GABASIGN 300 CAP is a pharmaceutical-grade anticonvulsant formulation developed with Gabapentin 300 mg, designed for the effective treatment of partial seizures, nerve-related pain disorders, and a range of neurological conditions. Gabapentin works by modulating the activity of calcium channels in the nervous system, which helps reduce abnormal electrical activity in the brain and alleviate chronic nerve pain.

Manufactured by BluepillExpress, a WHO-GMP and ISO-certified third-party pharmaceutical exporter, GABASIGN 300 CAP adheres to stringent international quality protocols. It is made using premium APIs sourced from validated suppliers, ensuring high bioavailability, consistent potency, and therapeutic reliability across global markets.

Therapeutic Indications

Neuropathic Pain associated with diabetic neuropathy, spinal cord injury, or shingles

Postherpetic Neuralgia (pain after shingles)

Partial Seizures (with or without secondary generalization)

Fibromyalgia and Chronic Nerve Disorders

Adjunct therapy for epilepsy

Mechanism of Action

Although structurally similar to GABA, Gabapentin does not bind to GABA receptors. Instead, it binds to the alpha-2-delta subunit of voltage-gated calcium channels, reducing the release of excitatory neurotransmitters. This action modulates pain signaling and stabilizes neural activity, providing relief from chronic pain and seizures.

Dosage & Administration

Neuropathic Pain: Typically starts at 300 mg once daily, titrated up to 900–1800 mg/day

Seizures (adjunct): 300 mg TID (initial), adjusted as required

Postherpetic Neuralgia: Start at 300 mg once daily, titrated gradually

Dosage should be individualized and prescribed by a medical professional.